GINWA ENTERPRISE (GROUP) INC. — Investor Relations & Filings
About GINWA ENTERPRISE (GROUP) INC.
Ginwa Enterprise (Group) Inc. operates as a diversified conglomerate focused on the research, development, manufacturing, and distribution of medical products. The company's portfolio includes traditional Chinese medicines, chemical drugs, and biological preparations targeting therapeutic areas such as cardiovascular health, anti-infectives, and digestive disorders. In addition to its medical operations, the group is involved in high-tech development, real estate, and strategic investment activities. The organization prioritizes technological innovation and adheres to rigorous quality control standards across its production facilities. It serves a broad market base, focusing on the modernization of traditional medicinal practices and the integration of advanced biotechnology into its product offerings.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 金花企业（集团）股份有限公司2026年度投资者关系管理计划 | 2026-04-28 | Chinese | |
| 金花企业（集团）股份有限公司董事、高级管理人员薪酬考核管理制度 | 2026-04-28 | Chinese | |
| 金花企业（集团）股份有限公司关于董事会换届选举的公告 | 2026-04-28 | Chinese | |
| 金花企业（集团）股份有限公司董事会关于2025年度保留意见审计报告和否定意见内部控制审计报告涉及事项的专项说明 | 2026-04-28 | Chinese | |
| 金花企业（集团）股份有限公司关于2025年度会计师事务所履职情况评估报告 | 2026-04-28 | Chinese | |
| 金花企业（集团）股份有限公司第十届董事会第二十九次会议决议公告 | 2026-04-28 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 40286944 | 金花企业（集团）股份有限公司2026年度投资者关系管理计划 | 2026-04-28 | Chinese | ||
| 40286932 | 金花企业（集团）股份有限公司董事、高级管理人员薪酬考核管理制度 | 2026-04-28 | Chinese | ||
| 40286903 | 金花企业（集团）股份有限公司关于董事会换届选举的公告 | 2026-04-28 | Chinese | ||
| 40286894 | 金花企业（集团）股份有限公司董事会关于2025年度保留意见审计报告和否定意见内部控制审计报告涉及事项的专项说明 | 2026-04-28 | Chinese | ||
| 40286888 | 金花企业（集团）股份有限公司关于2025年度会计师事务所履职情况评估报告 | 2026-04-28 | Chinese | ||
| 40286878 | 金花企业（集团）股份有限公司第十届董事会第二十九次会议决议公告 | 2026-04-28 | Chinese | ||
| 40286865 | 金花企业（集团）股份有限公司关于前期会计差错更正的公告 | 2026-04-28 | Chinese | ||
| 40286859 | 金花企业（集团）股份有限公司关于使用暂时闲置资金进行委托理财及证券投资的公告 | 2026-04-28 | Chinese | ||
| 40286850 | 独立董事提名人声明与承诺（吴雅婕） | 2026-04-28 | Chinese | ||
| 40286830 | 金花企业（集团）股份有限公司2026年第一季度报告 | 2026-04-28 | Chinese | ||
| 40286815 | 金花企业（集团）股份有限公司关于实施其他风险警示暨停牌的公告 | 2026-04-28 | Chinese | ||
| 40286814 | 独立董事候选人声明与承诺（吴雅婕） | 2026-04-28 | Chinese | ||
| 40286806 | 金花企业（集团）股份有限公司关于2025年度募集资金存放、管理与实际使用情况的专项报告 | 2026-04-28 | Chinese | ||
| 40286797 | 金花企业（集团）股份有限公司2025年年度报告摘要 | 2026-04-28 | Chinese | ||
| 40286793 | 关于对金花企业（集团）股份有限公司2025年度财务报表出具保留意见审计报告的专项说明 | 2026-04-28 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
GINWA ENTERPRISE (GROUP) INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56468/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56468 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56468 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56468 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56468}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GINWA ENTERPRISE (GROUP) INC. (id: 56468)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.